The approval of ICIs, including anti-CTLA-4, anti-PD-1, and anti-PD-L1 antibodies, has led to durable clinical responses and long-term remissions in various cancers, including CRC (Topalian et al., 2012). This evidence concerns the gene CD274 and cancer.